Last reviewed · How we verify
Ceftriaxone intravenous — Competitive Intelligence Brief
phase 3
Third-generation cephalosporin
Penicillin-binding proteins (PBPs)
Infectious Disease
Small molecule
Live · refreshed every 30 min
Target snapshot
Ceftriaxone intravenous (Ceftriaxone intravenous) — Fundación Pública Andaluza para la gestión de la Investigación en Sevilla. Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins and blocking cross-linking of peptidoglycan.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Ceftriaxone intravenous TARGET | Ceftriaxone intravenous | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | phase 3 | Third-generation cephalosporin | Penicillin-binding proteins (PBPs) | |
| Fortaz | Ceftazidime | Pai Holdings Pharm | marketed | Third-generation cephalosporin | Bacterial cell wall | 1985-01-01 |
| Cefdinir (drug) | Cefdinir (drug) | University of Chicago | marketed | Third-generation cephalosporin | Penicillin-binding proteins (PBPs) | |
| cefdinir (Omnicef) | cefdinir (Omnicef) | Abbott | marketed | Third-generation cephalosporin | Penicillin-binding proteins (PBPs) | |
| Ceftriaxone for Injection | Ceftriaxone for Injection | The University of Queensland | marketed | Third-generation cephalosporin | Penicillin-binding proteins (PBPs) | |
| Ceftazidime Injection | Ceftazidime Injection | Murdoch Childrens Research Institute | marketed | Third-generation cephalosporin | Penicillin-binding proteins (PBPs) | |
| Omnicef Cap. | Omnicef Cap. | Korea United Pharm. Inc. | marketed | Third-generation cephalosporin | Penicillin-binding proteins (PBPs) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Third-generation cephalosporin class)
- Abbott · 1 drug in this class
- Centre Hospitalier Universitaire de Besancon · 1 drug in this class
- Dr. Damon Scales · 1 drug in this class
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla · 1 drug in this class
- Kamuzu University of Health Sciences · 1 drug in this class
- Korea United Pharm. Inc. · 1 drug in this class
- Merck Sharp & Dohme LLC · 1 drug in this class
- Murdoch Childrens Research Institute · 1 drug in this class
- Pai Holdings Pharm · 1 drug in this class
- RESnTEC, Institute of Research · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Ceftriaxone intravenous CI watch — RSS
- Ceftriaxone intravenous CI watch — Atom
- Ceftriaxone intravenous CI watch — JSON
- Ceftriaxone intravenous alone — RSS
- Whole Third-generation cephalosporin class — RSS
Cite this brief
Drug Landscape (2026). Ceftriaxone intravenous — Competitive Intelligence Brief. https://druglandscape.com/ci/ceftriaxone-intravenous. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab